Literature DB >> 24518228

4-Methylcatechol prevents derangements of brain-derived neurotrophic factor and TrkB-related signaling in anterior cingulate cortex in chronic pain with depression-like behavior.

Kozo Ishikawa1, Seiko Yasuda, Kayoko Fukuhara, Yasutake Iwanaga, Yuika Ida, Junko Ishikawa, Hirotaka Yamagata, Midori Ono, Takahiro Kakeda, Toshizo Ishikawa.   

Abstract

Chronic pain with mood disorder, resulting from a peripheral nerve injury, is a serious clinical problem affecting the quality of life. A lack of brain-derived neurotrophic factor (BDNF) and abnormal intercellular signaling in the brain can mediate this symptom. BDNF is induced in cultured neurons by 4-methylcatechol (4-MC), but little is known about its role in pain-emotion. Thus, we characterized the actions of 4-MC on TrkB receptor-related pERK and BDNF mRNA in discreet brain regions related to pain-emotion after chronic pain in rat. Rats implanted with a stainless steel cannula into the lateral ventricular were subjected to chronic constriction injury (CCI). Pain was assessed by changes in paw withdrawal latency (PWL) to heat stimuli after CCI. Immobility time during the forced swimming testing was measured for depression-like behavior. Analgesic and antidepression modulations with 4-MC were examined by an anti-BDNF antibody (K252a, a TrkB receptor inhibitor). The animals were perfused and fixed (4% paraformaldehyde) for immunohistochemistry analysis (c-FOS/pERK). BDNF mRNA expression (anterior cingulate cortex) was determined using reverse transcription-PCR. Rats showed a sustained decrease in PWL, associated with a prolonged immobility time after CCI. 4-MC reduced decreases in PWL and increased immobility time. 4-MC reduced increases in pERK immunoreactivity and decreases in BDNF mRNA expression in regions related to pain and the limbic system. Anti-BDNF blocked effects induced by 4-MC. We suggest that a lack of BDNF associated with activated extracellular signal-regulated kinase in the pain-emotion network may be involved in depression-like behavior during chronic pain. 4-MC ameliorates pain-emotion symptoms by inducing BDNF and normalizing pERK activities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24518228     DOI: 10.1097/WNR.0000000000000072

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  6 in total

1.  Imipramine ameliorates pain-related negative emotion via induction of brain-derived neurotrophic factor.

Authors:  Seiko Yasuda; Mitsuhiro Yoshida; Hirotaka Yamagata; Yasutake Iwanaga; Hiromi Suenaga; Kozo Ishikawa; Masako Nakano; Satoshi Okuyama; Yoshiko Furukawa; Shoei Furukawa; Toshizo Ishikawa
Journal:  Cell Mol Neurobiol       Date:  2014-08-26       Impact factor: 5.046

2.  Fos Protein as a Marker of Neuronal Activity: a Useful Tool in the Study of the Mechanism of Action of Natural Products with Analgesic Activity.

Authors:  Priscila L Santos; Renan G Brito; João Pedro S C F Matos; Jullyana S S Quintans; Lucindo J Quintans-Júnior
Journal:  Mol Neurobiol       Date:  2017-07-10       Impact factor: 5.590

3.  Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI).

Authors:  Jia Zhao; Dan Luo; Zhaohui Liang; Lixing Lao; Jianhui Rong
Journal:  Mol Neurobiol       Date:  2016-03-24       Impact factor: 5.590

4.  EXPRESS: NGF-trkA signaling modulates the analgesic effects of prostatic acid phosphatase in resiniferatoxin-induced neuropathy.

Authors:  Chieh-Hsin Wu; Wan-Yi Ho; Yi-Chen Lee; Chih-Lung Lin; Yu-Lin Hsieh
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

5.  Neurotropin(®) ameliorates chronic pain via induction of brain-derived neurotrophic factor.

Authors:  Toshizo Ishikawa; Seiko Yasuda; Seiji Minoda; Takae Ibuki; Kayoko Fukuhara; Yasutake Iwanaga; Toru Ariyoshi; Hironori Sasaki
Journal:  Cell Mol Neurobiol       Date:  2014-10-05       Impact factor: 4.231

Review 6.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.

Authors:  Marie Fitzgibbon; David P Finn; Michelle Roche
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-05       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.